The Spark, Medicon Village
223 81 Lund, Sweden
Diagonal Bio is developing a diagnostic platform for ultra-rapid, parallel, accurate and cost-efficient detection of any kind of pathogen – Panviral.
Panviral provides major benefits for the healthcare system. The small size, extreme ease-of-use, parallelity, limited pre-treatment time and low cost of the platform means that a reliable diagnostic test can be carried out at the point-of-care, without the need to send samples to a central lab.
With Panviral, correct and highly accurate diagnoses is achieved at a fraction of the cost, time and expertise required by current methods, such as PCR. The speed, mobility, parallelisation and ease-of-use also mean – for the current pandemic as well as for future needs – that testing facilities can be set up basically anywhere.
Multiple tests can be run in parallel, thereby significantly increasing the sample throughput. Tailor-made diagnostic cocktails enable simultaneous testing for related and hard-to-distinguish diseases – all from the same patient sample. Consequently, the Panviral technology is easily scalable and lends itself perfectly to automated high-throughput screening of virtually any type of pathogen.
Panviral’s technology is based on rapid isothermal amplification of a pathogen’s genome. The reaction is tracked in real-time, for an ultra-rapid and quantitative result. Test progress is monitored using a proprietary and patent-pending electrochemical sensing method.